AI Article Synopsis
- Recent clinical trials show that pegcetacoplan and avacincaptad pegol, which inhibit C3 and C5 respectively, can reduce GA growth by around 20% in a dose-dependent manner.
- However, while these treatments slow the progression of GA, they do not improve visual function and may lead to serious side effects like conversion to other eye diseases and retinal issues.
Article Abstract
Geographic atrophy (GA) affects around 5 million individuals worldwide. Genome-wide, histopathologic, in vitro and animal studies have implicated the activation of the complement system and chronic local inflammation in the pathogenesis of GA. Recently, clinical trials have demonstrated that an intravitreal injection of pegcetacoplan, a C3 inhibitor, and avacincaptad pegol, a C5 inhibitor, both statistically significantly reduce the growth of GA up to 20% in a dose-dependent fashion. Furthermore, the protective effect of both pegcetacoplan and avacincaptad appear to increase with time. However, despite these anatomic outcomes, visual function has not improved as these drugs appear to only slow down the degenerative process. Unexpected adverse events included conversion to exudative NV-AMD with both drugs. Occlusive retinal vasculitis and anterior ischemic optic neuropathy have been reported in pegcetacoplan-treated eyes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420150 | PMC |
| http://dx.doi.org/10.3390/jcm12155131 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and Imaging Characteristics of PRPH2 Retinopathies in a Longitudinal Cohort and Diagnostic Implications.
Invest Ophthalmol Vis Sci
December 2024
Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, United States.
Purpose: The purpose of this study was to define genotypic-phenotypic correlations related to PRPH2-associated retinopathies in an observational longitudinal cohort and to improve diagnostic accuracy.
Methods: Individuals with PRPH2 variants were identified by genetic sequencing of 263 individuals (including 59 families). Ocular examinations with multimodal imaging were evaluated.
Photoreceptor-RPE loss ratio and fundus autofluorescence patterns as predictive factors for lesion progression in geographic atrophy.
Acta Ophthalmol
December 2024
Department of Ophthalmology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.
Purpose: To assess the impact of the ratio between photoreceptor (PR) loss and retinal pigment epithelium (RPE) loss on the progression of geographic atrophy (GA) and to explore correlations between abnormal fundus autofluorescence (FAF) patterns and the PR-RPE loss ratio.
Design: Single-centre, retrospective case series.
Methods: Multimodal images from 87 treatment-naïve patients with GA and a follow-up of 6-24 months were included.
Characterizing Patient Perceptions of Living with Geographic Atrophy: The Global Geographic Atrophy Insights Survey.
Clin Ophthalmol
December 2024
Retina Services, Pepose Vision Institute, Chesterfield, MO, USA.
Background: Geographic atrophy (GA) is an advanced form of age-related macular degeneration leading to irreversible vision loss and negative impacts on quality of life.
Methods: To assess the experiences of living with GA, the Geographic Atrophy Insights Survey (GAINS) was conducted between October 12, 2021, and December 10, 2021, captured the responses of individuals ≥60 years with a self-reported GA diagnosis residing in the United States, Canada, Australia, and six European countries. Survey questions focused on the perceptions of individuals living with GA and covered six themes: speed of disease progression, effect on independence, impact on quality of life, emotional toll of GA, misconceptions and need for further education about GA, and clinician interactions.
Inherited Retinal Degenerations and Non-Neovascular Age-Related Macular Degeneration: Progress and Unmet Needs.
Transl Vis Sci Technol
December 2024
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Inherited retinal degeneration (IRD) disease and age-related macular degeneration (AMD) are leading causes of irreversible vision loss and blindness. Although significant progress has advanced the field in the past 5 years, significant challenges remain. The current article reviews the accomplishments and research advances that have fueled the development of treatments for patients with IRD and AMD, including the first approved gene-augmentation treatment for RPE65-related retinal degeneration and complement inhibition therapies to slow progression of geographic atrophy (GA) in AMD.
View Article and Find Full Text PDFSafety Profile and Practical Applications of the C3 and C5 Complement Inhibitors for Management of Geographic Atrophy.
Ophthalmic Surg Lasers Imaging Retina
December 2024
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!